Abstract
e19094 Background: Afatinib (BIBW-2992) has been approved for patients with untreated metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon 21 L858R substitution mu...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have